The development of new drug therapies has historically been a slow and expensive journey, often taking decades and billions of dollars before reaching patients. Today, artificial intelligence is changing that narrative, stepping in as a powerful partner in drug development and product life cycle management by accelerating discovery, reducing costs, and improving success rates across the entire pipeline.
AI’s alliance with pharmaceutical researchers is not entirely new. Algorithms have helped scientists test and refine drug molecules, helping them explore chemical structures more efficiently than traditional trial-and-error methods.
What has changed in recent years is the scale and sophistication of these tools. Today’s advances in data analysis and machine learning allow researchers to process massive datasets and predict outcomes with remarkable accuracy. By filtering out ineffective compounds early, AI shortens discovery timelines, reduces research and development costs, and hastens the availability of life-saving medications.
Read the full article by Dr. Jared Auclair in the Boston Business Journal here.
